Business Context and Reporting Period
This Form 6-K filing by InflaRx N.V. covers the month of March 2021. The report discloses a significant capital raising event where the Company entered into an Underwriting Agreement on January 25, 2021, with Guggenheim Securities, LLC, to facilitate an offering of common shares and warrants.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the structural details of a securities offering rather than operational financial performance.
Material Changes
The primary material change disclosed is the execution of an Underwriting Agreement for the sale of:
- 15,000,000 common shares.
- 15,000,000 warrants to purchase an aggregate of 15,000,000 common shares.
This offering was made pursuant to an effective shelf registration statement on Form F-3 (Registration No. 333-239759), with a final prospectus supplement dated February 25, 2021.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the standard legal disclosures regarding the legality of the issuance. The document incorporates by reference the Underwriting Agreement and legal opinions from NautaDutilh N.V. and Kirkland & Ellis LLP regarding the legality of the share and warrant issuance.
Investor Verification Checklist
- Verify the final prospectus supplement dated February 25, 2021, for the specific offering price and total capital raised.
- Review the Underwriting Agreement (Exhibit 99.1) for details on underwriting fees, lock-up periods, and use of proceeds.
- Confirm the exercise price and expiration terms of the 15,000,000 warrants issued.
- Check subsequent filings for the actual closing date and net proceeds received from the offering.